BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Japan flag Japan · Delayed Price · Currency is JPY
51.00
-1.00 (-1.92%)
Jul 16, 2026, 10:13 AM JST
Market Cap7.22B +85.6%
Revenue (ttm)84.00K -92.6%
Net Income-1.30B
EPSn/a
Shares Out 138.89M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume344,200
Open52.00
Previous Close52.00
Day's Range50.00 - 52.00
52-Week Range43.00 - 114.00
Beta1.28
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About TYO:4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 42
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4594
Full Company Profile

Financial Performance

In fiscal year 2026, TYO:4594's revenue was 84,000, a decrease of -92.59% compared to the previous year's 1.13 million. Losses were -1.30 billion, 13.4% more than in 2025.

Financial Statements